You can buy or sell uniQure and other stocks, options, ETFs, and crypto commission-free!
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. Read More The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
52 Week High
52 Week Low
Stock Price, News, & Analysis for Uniqure
News articles about QURE stock have been trending positive this week, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Uniqure earned a daily sentiment score of 2.2 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 5.0...
Guru FocusMar 1
uniQure to Participate in Multiple Upcoming Industry Conferences
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 01, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. ( QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in March: Leerink Global Health Care Conference in New York City Matt Kapusta , chief executive officer at uniQure, will participate in a fireside chat on Friday, March 1 at 9:30 a.m. ET. The live webcast can be acces...
Expected Apr 30, Pre-Market